Key result
Low endogenous homoarginine levels are associated with an increased risk of adverse cardiovascular outcomes, highlighting its potential as a prognostic factor and therapeutic target.
Why the study?
Recent epidemiological studies have linked low l-homoarginine levels to adverse cardiovascular outcomes, raising interest in its potential as a treatable protective risk factor.
Does homoarginine act as a protective cardiovascular risk factor?
Design
Review
Authors
Loading...
Homoarginine may inform cardiovascular prognosis; randomized trials needed to test therapeutic targeting.
This review highlights the emergence of homoarginine as a potentially treatable protective cardiovascular risk factor, identifying priorities for future research to define its clinical utility.
Karetnikova et al. (2019) conducted a review in Cardiovascular disease. Homoarginine was evaluated. Low endogenous homoarginine levels are associated with an increased risk of adverse cardiovascular outcomes, highlighting its potential as a prognostic factor and therapeutic target.